Profile: Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,822.25INR
6:17am EDT
Price Change (% chg)

Rs55.55 (+2.01%)
Prev Close
Rs2,766.70
Open
Rs2,766.00
Day's High
Rs2,852.00
Day's Low
Rs2,766.00
Volume
48,206
Avg. Vol
34,929
52-wk High
Rs2,939.80
52-wk Low
Rs2,025.00

Search Stocks
Dr. Reddy’s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL’s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.

Company Address

Dr.Reddy's Laboratories Ltd

8-2-337
Road No.3, BANJARA HILLS, Telang
HYDERABAD     500034
P: +9140.49002900
F: +9140.49002999

Search Stocks